Cyclo Therapeutics Seeks FDA Approval for Remibetadex to Treat NPC
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Kion Publishes Q3 2026 Results Call Transcript
Kion published a transcript of its Q3 2026 results update call.
M impact | EQUITY | Oct 29, 2026, 07:20 PM UTC
Alnylam Reports Quarterly Results Through September 30
Alnylam Pharmaceuticals reported results for the quarter ended September 30. The alert provides no financial figures.
M impact | EQUITY | Oct 29, 2026, 07:15 PM UTC
Riverview Bancorp Reports $2.0 Million Second-Quarter Profit
Riverview Bancorp reported net income of $2.0 million, or $0.10 per diluted share, for the fiscal second quarter ended September 30, 2026. Net interest income was $11.8 million and
M impact | EQUITY | Oct 29, 2026, 07:13 PM UTC
Ligand Pharmaceuticals Reports Quarterly Results Through September 30
M impact | EQUITY | Oct 29, 2026, 07:13 PM UTC
Allegro Microsystems Reports Quarterly Results Through September 30
M impact | EQUITY | Oct 29, 2026, 07:12 PM UTC
Group 1 Automotive Reports Third-Quarter Revenue of $5.4B
Third-quarter revenue fell 6.7% year over year to $5.4 billion. Net income rose to $102.9 million from $13 million; diluted EPS was $8.59.
M impact | EQUITY | Oct 29, 2026, 07:11 PM UTC